Weekly Research Analysts’ Ratings Updates for Zymeworks (ZYME)

Several analysts have recently updated their ratings and price targets for Zymeworks (NASDAQ: ZYME):

• 10/15/2026 – Zymeworks had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/7/2026 – Zymeworks had its price target raised by Truist Financial Corporation from $32.00 to $34.00. They now have a “buy” rating on the stock.
• 9/29/2026 – Zymeworks had its “buy” rating reaffirmed by Citigroup Inc.. They now have a $39.00 price target on the stock, up from $38.00.
• 9/29/2026 – Zymeworks is now covered by TD Cowen. They set a “buy” rating and a $34.00 price target on the stock.
• 9/17/2026 – Zymeworks is now covered by Wolfe Research. They set an “outperform” rating on the stock.
• 9/3/2026 – Zymeworks had its price target raised by JPMorgan Chase & Co. from $31.00 to $33.00. They now have an “overweight” rating on the stock.
• 8/26/2026 – Zymeworks was given a new $32.00 price target by Deutsche Bank Aktiengesellschaft.
• 8/26/2026 – Zymeworks had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/26/2026 – Zymeworks had its price target raised by Citigroup Inc. from $37.00 to $38.00. They now have a “buy” rating on the stock.
• 8/26/2026 – Zymeworks had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $32.00 price target on the stock.
• 8/26/2026 – Zymeworks had its price target raised by HC Wainwright from $51.00 to $55.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at Zymeworks

In other news, EVP Adam Schayowitz sold 13,832 shares of the stock in a transaction on Friday, October 9th. The shares were sold at an average price of $25.85, for a total value of $357,557.20. Following the sale, the executive vice president owned 23,205 shares in the company, valued at $599,849.25. This represents a 37.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 33.51% of the stock is owned by insiders.

Zymeworks Inc (NASDAQ: ZYME) is a biopharmaceutical company focused on discovering, developing and commercializing engineered antibody-based therapeutics for cancer and other serious diseases. The company’s technologies are designed to create bispecific and multispecific antibodies, as well as antibody-drug conjugates that can target tumor cells and deliver therapeutic payloads.

Zymeworks’ leading product is zanidatamab, marketed in the United States as Ziihera. The bispecific antibody targets two separate sites on the HER2 protein and received U.S.